Geniposide alleviates lipopolysaccharide-caused apoptosis of murine kidney podocytes by activating Ras/Raf/MEK/ERK-mediated cell autophagy
Source abstract
Abstract
Proteinuria is one of the most important clinical features of nephrotic syndrome (NS). Injury of podocyte has been proved to contribute to the occurrence of proteinuria. This study explored the effects of geniposide (GEN) on lipopolysaccharide (LPS)-caused murine kidney podocyte MPC5 apoptosis and autophagy. Viability and apoptosis of MPC5 cells were respectively detected with the help of CCK-8 assay and Guava Nexin assay. 3-Methyladenine (3-MA) was used as an autophagy inhibitor, while rapamycin as autophagy activator. Si-Beclin-1 was transfected in MPC5 cells to down-regulate the expression of Beclin-1. We found that LPS stimulation significantly caused MPC5 cell viability reduction, apoptosis and autophagy (P < .05 or P < .01). GEN treatment remarkably alleviated the LPS-caused MPC5 cell viability reduction and apoptosis, but promoted cell autophagy (P < .05). Moreover, 3-MA incubation or si-Beclin-1 transfection notably weakened the effects of GEN on LPS-caused MPC5 cell apoptosis and autophagy (P < .05), while rapamycin had opposite effects (P < .05). Furthermore, GEN activated Ras/Raf/MEK/ERK pathway in LPS-treated MPC5 cells (P < .05). In conclusion, this research verified the protective effects of GEN on podocytes damage. GEN alleviates LPS-caused apoptosis of murine kidney podocytes by activating Ras/Raf/MEK/ERK-mediated cell autophagy. Highlights: LPS causes podocyte MPC5 apoptosis and autophagy. GEN alleviates LPS-caused MPC5 cell apoptosis, but promotes cell autophagy. 3-MA or si-Beclin-1 weakens the effects of GEN on LPS-treated MPC5 cells. Rapamycin strengthens the effects of GEN on LPS-treated MPC5 cells. GEN activates Ras/Raf/MEK/ERK pathway in LPS-treated MPC5 cells.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Renal Diseases and Glomerulopathies · Biomedical Research and Pathophysiology · Autophagy in Disease and Therapy
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Nephrology, Jining No.1 People’s Hospital
Affiliated Jining No.1 People's Hospital of Jining Medical University, Jining Medical University
Department of Nephrology, The Ninth People’s Hospital of Chongqing
References (36)
Show source-provided references
1. Kodner C. Diagnosis and management of nephrotic syndrome in adults. Am Fam Physician. 2016;93:479–485.
2. 10.4103/2229-5151.18301910.4103/2229-5151.183019 ↗
3. 10.1024/1661-8157/a00229610.1024/1661-8157/a002296 ↗
4. Rheault MN, Gbadegesin RA. The genetics of nephrotic syndrome. J Pediatr Genet. 2016;5:15–24.
5. 10.1152/ajprenal.00136.201510.1152/ajprenal.00136.2015 ↗
6. 10.5604/17322693.120120210.5604/17322693.1201202 ↗
7. Qi Q, Mao Y, Tian Y, et al. Geniposide inhibited endothelial-mesenchymal transition via the mTOR signaling pathway in a bleomycin-induced scleroderma mouse model. Am J Translation Res. 2017;9:1025–1036.
8. 10.3390/molecules2210168910.3390/molecules22101689 ↗
9. 10.1159/00048065710.1159/000480657 ↗
10. 10.1016/j.transproceed.2017.02.06310.1016/j.transproceed.2017.02.063 ↗
11. 10.1016/j.micpath.2017.09.05010.1016/j.micpath.2017.09.050 ↗
12. 10.1016/j.neuint.2007.04.02110.1016/j.neuint.2007.04.021 ↗
13. 10.3892/etm.2016.401110.3892/etm.2016.4011 ↗
14. 10.1016/j.intimp.2013.06.02810.1016/j.intimp.2013.06.028 ↗
15. 10.1016/j.mce.2016.04.02010.1016/j.mce.2016.04.020 ↗
16. Wu W, Yang JJ, Wan YG, et al. Pathogenesis and treatment of insulin resistance in chronic kidney disease and interventional effects of Chinese herbal medicine. China J Chinese Materia Medica. 2017;42:49–55.
17. 10.1186/s12974-018-1233-210.1186/s12974-018-1233-2 ↗
18. 10.1038/s41598-017-00564-310.1038/s41598-017-00564-3 ↗
19. 10.1007/s40620-016-0361-y10.1007/s40620-016-0361-y ↗
20. 10.3109/00365599.2012.74882110.3109/00365599.2012.748821 ↗
21. 10.3390/nu801004110.3390/nu8010041 ↗
22. 10.1128/IAI.73.8.5194-5197.200510.1128/IAI.73.8.5194-5197.2005 ↗
23. 10.1016/j.biopha.2017.05.12210.1016/j.biopha.2017.05.122 ↗
24. 10.1016/j.phymed.2014.08.00210.1016/j.phymed.2014.08.002 ↗
25. 10.1152/ajprenal.00162.201610.1152/ajprenal.00162.2016 ↗
26. 10.1681/ASN.200502014210.1681/ASN.2005020142 ↗
27. 10.1007/s00125-007-0821-y10.1007/s00125-007-0821-y ↗
28. 10.1016/j.cellsig.2013.11.02810.1016/j.cellsig.2013.11.028 ↗
29. 10.1152/ajpcell.00424.200910.1152/ajpcell.00424.2009 ↗
30. 10.3892/mmr.2016.530110.3892/mmr.2016.5301 ↗
31. 10.4062/biomolther.2015.02510.4062/biomolther.2015.025 ↗
32. 10.1002/bit.2456710.1002/bit.24567 ↗
33. 10.4161/auto.678710.4161/auto.6787 ↗
34. 10.1002/ijc.3139810.1002/ijc.31398 ↗
35. 10.1016/j.bbamcr.2006.10.00110.1016/j.bbamcr.2006.10.001 ↗
36. 10.1158/0008-5472.CAN-05-355710.1158/0008-5472.CAN-05-3557 ↗